Diclofenac sodium is a widely used nonsteroidal anti-inflammatory drug (NSAID) for relief of inflammatory pain. A recent formulation combines this drug with hydroxypropyl-β-cyclodextrin (HPβCD) to improve its solubility and to enable subcutaneous administration. Previous studies confirmed the efficacy of this combination. This study's aim was to evaluate the efficacy, safety, and local tolerability of diclofenac HPβCD administered as a local submucosal injection prior to lower third molar surgery. We conducted a prospective, randomized, double-blind, placebo-controlled, parallel-group phase II single-center study. Seventy-five patients requiring mandibular third molar surgery were randomized into 1 of 5 groups: 5 mg/1 mL diclofenac HPβCD, 12.5 mg/1 mL diclofenac HPβCD, 25 mg/1 mL diclofenac HPβCD, 50 mg/1 mL diclofenac HPβCD, or 1 mL placebo. The respective study drug was injected into the mucosal tissue surrounding the surgical site prior to surgery following achievement of local anesthesia. The primary outcome measure was the area under the curve (AUC) of cumulative pain scores from end of surgery to 6 h postsurgery. This demonstrated a global treatment effect between the active groups and placebo, hence confirming the study drug's efficacy (P = 0.0126). Secondary outcome measures included the time until onset of pain and the time until patients required rescue medication, both showing statistical significance of the study drug compared to placebo (P < 0.0161 and P < 0.0001, respectively). The time until rescue medication ranged between 7.8 h (for 25 mg/1 mL diclofenac HPβCD) and 16 h (for 50 mg/1 mL diclofenac HPβCD). Interestingly, the 5-mg/1-mL solution appeared superior to the 12.5-mg/1-mL and 25-mg/1-mL solutions (time until rescue medication = 12.44 h). A total of 14% of patients experienced minor adverse drug reactions (ADRs), of which 2 cases demonstrated flap necrosis. These resolved without further intervention. The study results overall indicate efficacy, safety, and relative tolerability of diclofenac HPβCD used locally as a submucosal injection prior to third molar surgery (ClinicalTrials.gov NCT01706588).
Introduction
Diclofenac is a well-established nonselective nonsteroidal anti-inflammatory drug (NSAID). Due to its anti-inflammatory, antipyretic, and analgesic properties, it is commonly used to treat acute/chronic pain and inflammation (Sengupta et al. 1985; Barden et al. 2004; Hersh et al. 2004; Moore 2007; Gan 2010; Blair and Plosker 2015; Moore, Wiffen, et al. 2015) . Diclofenac sodium's acidic form is poorly soluble (Sengupta et al. 1985) and therefore available as the sodium salt with pharmaceutically acceptable solvents (e.g., propylene glycol and benzyl alcohol) to enable intramuscular (IM) and intravenous administration. Recent formulations use the complexing agent hydroxypropyl-β-cyclodextrin (HPβCD), serving as a solubility enhancer and facilitating smaller volumes for subcutaneous (SC) or submucosal application (Albers and Muller 1995; Blair and Plosker 2015) , with previous studies confirming its successful and safe SC use (Zeitlinger et al. 2012; Dietrich et al. 2014; Chiarello et al. 2015) .
Local submucosal drug injection is well-established with local anesthetics but otherwise rarely used. The submucosal injection of dexamethasone (Moraschini et al. 2016; Saravanan et al. 2016; Chen et al. 2017) in the context of lower third molar (LM3) surgery is a notable exception. Submucosal injection of analgesics has been described with ketorolac in endodontic pain management (Penniston and Hargreaves 1996) and tramadol in LM3 surgery (Ceccheti et al. 2014) , combining the advantages of parenteral drug administration with an administration route that every dentist will be comfortable with. Both studies evaluated standard analgesic doses of the respective analgesic drug.
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However, we hypothesized that local submucosal injection of diclofenac may achieve analgesia at markedly lower than standard analgesic doses, taking advantage of high concentrations locally at the site of tissue insult. This would be an attractive novel concept, potentially achieving analgesia while minimizing side effects. We planned the present study to meet 2 objectives: 1) to provide proof of principle or otherwise of low-dose local analgesia and 2) to evaluate the potential for submucosal diclofenac HPβCD as a preemptive analgesic in LM3 surgery, as this would have immediate clinical application, if effective. The aim of the present study was therefore to investigate the efficacy, local tolerability, and safety of preemptive submucosal injection of different diclofenac HPβCD doses for postoperative analgesia in a phase II proofof-principle study.
Materials and Methods
Study Design
This investigator-initiated trial was a prospective, randomized, double-blind, placebo-controlled, parallel-group, phase II singlecenter study, conducted at The School of Dentistry, University of Birmingham at Birmingham Dental Hospital, Birmingham, United Kingdom. Ethical approval was obtained by the Ethics Committee, Office for Research Ethics Committees Northern Ireland. The trial adhered to the Declaration of Helsinki and the International Conference on Harmonisation (IHC) consolidated guideline on Good Clinical Practice (GCP).
Patients (aged 18 to 65 y), referred for the surgical removal of a LM3 under local anesthesia (LA) requiring osteotomy, were eligible to participate (please see online appendix for full list of inclusion/exclusion criteria). Written informed consent had to be provided to be enrolled.
Intervention
Patients received 1 of 4 diclofenac HPβCD (Akis/Dicloin; IBSA) doses (50 mg/1 mL, 25 mg/1 mL, 12.5 mg/1 mL, or 5 mg/1 mL) or 1 mL placebo (sterile water, Appendix Fig. 1 ).
Randomization, Allocation Concealment, and Blinding
The investigational drug and preparation instructions were supplied packed in identical, sealed boxes, numbered sequentially according to a predefined, computer-generated randomization list in blocks of 10 (i.e., with 2 kits for each treatment dose level). No stratification was used. None of the investigators were aware of the randomization method for the duration of the study to minimize risk of selection bias. Following confirmation of all eligibility criteria on the surgery day, the next available randomization number was allocated to the patient. A single trained study team member (P.T.), not involved in any other study procedure, opened the corresponding study medication pack and prepared the syringe for injection in a separate room. Placebo, 25-mg, and 50-mg ampoules appeared identical; however, 5-mg and 12.5-mg formulations were prepared by diluting a 25-mg ampoule with water for injection, with relevant instructions being contained in the medication pack. All 1-mL syringes were delivered unmarked to the surgeon for administration. Neither the surgeon nor any other study team member was made aware of its contents.
Surgery and Follow-up
Experienced oral surgeons performed the LM3 removal within 30 d of the screening visit using a standard surgical protocol (see Appendix). The study medication was injected in 3 sites buccal to the LM3 (approximately equal distance apart, about 0.33 mL per site), following achievement of LA.
During the postoperative 6-h observational period at the investigational site, pain measurements (using a 0-to 100-mm visual analog scale [VAS] ), the amount of rescue medication (RM) consumed (i.e., 500-mg paracetamol tablets) and surgical site appearance regarding bleeding and local irritancy/ tolerability were recorded. Patients were then discharged and continued to make hourly pain ratings and recorded any RM intake in a postoperative diary for a further 6 h. From the day after surgery, patients recorded the RM amount and an overall pain rating for each postoperative day (using a 0-to 100-mm VAS) on a daily basis for 1 wk.
Patients returned for 2 follow-up visits (days 2 and 7 postsurgery) to assess postoperative extraoral swelling, trismus, and wound healing and verify RM consumption.
Where required, extractions of any additional teeth were performed outside the trial.
Baseline/Surgical Data
A number of demographic, lifestyle, and surgical data were collected at the respective study visits (see Appendix).
Outcome Measures and Statistical Analyses
The primary end point was the area under the curve (AUC) of pain scores over time (assessed using 0-to 100-mm VAS), from end of surgery until 6 h postsurgery compared between treatment groups. Assuming a standard deviation of 20 mm and a mean difference (over the 6 h) between groups of 25 mm, a sample size of 12 patients per group would be required for 2-by-2 comparisons at α = 0.05 and 80% power. Therefore, 15 patients per group were considered sufficient to preliminarily investigate the treatment's efficacy.
The following secondary end points were evaluated (see Appendix for further details): Prespecified Analysis Plan. Baseline/surgical characteristics were summarized by treatment group to evaluate whether the groups were balanced at randomization, with mean/standard deviation used for continuous measures and number/percentage for categorical variables.
Baseline characteristics were compared between the study groups using analysis of variance (ANOVA) models and Fisher exact test.
Missing VAS pain scores or values after RM for the timed assessments in the 12-h postoperative period were replaced by using a linear interpolation method. For this purpose, the linear trend between the last 2 valid VAS scores was used to replace the missing value. Patients' pain ratings on postoperative days were not replaced, irrespective of timing of RM intake.
Three populations were considered for analysis: intention to treat (ITT), per protocol (PP), and safety population (see Appendix for details).
The primary end-point analysis was conducted using both ITT and PP. In addition to the unadjusted analyses, a multivariable analysis was performed, adjusting for body mass index (BMI), amount of bone removal, and sex in the ANOVA model. Post hoc testing for pairwise comparisons between active and placebo groups did not adjust for multiple comparisons.
All other end points were analyzed using the ITT principle. Safety variables (adverse events [AEs]) were assessed using the safety population.
Treatment effect estimates were reported with 95% confidence intervals and statistical tests performed at α = 0.05.
Results
We screened 80 patients between January and May 2013. Of the 75 randomized patients, 15 each were allocated to the 5-mg, 12.5-mg, and 25-mg diclofenac HPβCD groups; 14 to the 50-mg HPβCD group; and 16 to placebo (Appendix Fig. 1 ).
Protocol Violations
Two patients were excluded from the PP population due to major protocol violations, that is, missing or delayed (delay ≥15 min from scheduled time) pain measurements, which occurred in the 6-h postsurgery period.
Demographic/Surgical Characteristics
Demographic and surgical characteristics were overall well balanced between study groups (Table 1) . 
Efficacy Variables
Primary Outcome Measure. We found a global treatment effect in both ITT and PP populations (P = 0.0126 and P = 0.0057, respectively). In contrast, no statistically significant differences were found between the active study arms (Table 2 , Fig. 1 ). Adjustment for sex, BMI, and amount of bone removal as covariates also confirmed a global treatment effect between active and placebo arms (P = 0.0188). No statistically significant difference was noted between the diclofenac groups. Also, none of the covariates exerted an influence on the primary variable.
Secondary Outcome Measures. The AUC of VAS scores over the 12-h postoperative period revealed similar results to the 6-h postoperative period with the least square means (LSMs) being lower in the active groups compared with placebo (P = 0.0471). A global treatment effect was seen between the diclofenac groups and placebo apart from the comparison between 25 mg diclofenac HPβCD and placebo (P = 0.1093). No statistically significant differences were observed between active treatment groups (Table 2, Fig. 1) .
The active groups exhibited longer time until pain onset compared to placebo (P = 0.0161 for overall treatment effect). Again, no statistical differences were found between diclofenac groups (Table 2, Fig. 2 ).
The time until first RM was significantly shorter in the placebo group compared to the active treatment groups, demonstrating again a global treatment effect (P < 0.0001). Between the active groups, no statistically significant differences were observed (Table 2, Fig. 3 ).
The cumulative proportion of patients taking RM over the 6-h period postsurgery was higher in the placebo group compared with the diclofenac groups (P = 0.0483) ( Table 2) .
Peak pain intensity analysis showed no global treatment effect (P = 0.8595). Likewise, evaluation of trismus revealed no statistically significant differences between active groups and placebo, measured at 6 h (P = 0.1691), 2 d (P = 0.5428), and 7 d (P = 0.6260) postsurgery. Similar findings were observed for the extraoral swelling measured at 6 h (P = 0.3855) and 2 d (P = 0.5933). However, a global treatment effect was noted at 7 d after surgery, with a small but statistically significant difference in favor of the diclofenac groups compared to placebo (P = 0.0214) ( Table 2) .
Safety/Tolerability
AEs and adverse drug reactions (ADRs = AEs occurring after injection of study drug and with a causal relationship to the study drug, as judged by the investigator) were monitored throughout the study period. The causal relationship between AEs and the study drug was assessed at the time when the event occurred. The number of patients experiencing at least 1 AE was 8 (53.3%) in the 5-mg diclofenac group, 9 (60%) in the 12.5-mg group, 8 (53.3%) in the 25-mg group, and 5 (35.7%) in the 50-mg group. Six (37.5%) AEs were reported among placebo patients (Appendix Table 1 ). The number of participants experiencing AEs did not differ significantly between groups. The most frequently occurring AEs were headache, vomiting, and facial swelling (Appendix Table 2 ).
The percentage of ADRs was 13.3% in both the 5-mg and 12.5-mg diclofenac groups, 33.3% in the 25-mg group, and 14.3% in the 50-mg group. Placebo group patients did not report any ADRs (Appendix Table 1 ). The most frequent ADRs were injection site reactions (i.e., pain or swelling) (Appendix Table 3 ). Two cases of flap necrosis were observed during the postoperative observation period. One mild ulceration arose in the 25-mg group at the 2-d review appointment, and 1 moderate ulceration was observed in the 50-mg group at the 7-d review appointment (Appendix Figs. 2, 3) . These resolved spontaneously, without requiring any countermeasures. The number of ADRs did not differ significantly between groups.
No serious adverse events (SAEs) were recorded.
Discussion
This trial aimed at evaluating the safety, tolerability, and efficacy of varying doses of diclofenac HPβCD (5 mg, 12.5 mg, 25 mg, 50 mg) injected locally prior to LM3 surgery. The choice of diclofenac sodium as an anti-inflammatory analgesic for relief of moderate to severe dental pain is supported by 1) extensive studies reported from the Cochrane database (Barden et al. 2004; Moore 2007; Moore, Derry, et al. 2015b; Moore, Wiffen, et al. 2015) showing this drug's effectiveness in dental pain with low AE incidence encountered with other NSAIDs and analgesics (Gan 2010; Moore, Derry, et al. 2015a) ; 2) rapid absorption from oral/parenteral preparations and other favorable pharmacokinetic properties (Sengupta et al. 1985) , as well as its ability to accumulate into the cerebrospinal fluid and pain inhibition in the central nervous system (Björkman and Elam 1993; Kokki et al. 2008) ; and 3) its novel mechanism of analgesia involving selective effects on ion channels (Duan et al. 2012; Gwanyanya et al. 2012 ) quite separate from its well-known actions as a potent inhibitor of cyclooxygenases and inflammatory pain-producing prostaglandins (Gan 2010; Rainsford 2015) , lipoxygenases (Gan 2010) , nitric oxide-cGMP antinociceptive pathway activation, and NMDA-receptor analgesia (Gan 2010) . Some of these actions delineate diclofenac from other NSAIDs and may contribute to its potent effects as an acute pain-relieving drug.
All 4 drug dose levels produced significantly superior effects compared with placebo in preventing pain during the 6-h postsurgical observation period in terms of pain intensity levels, time until pain onset, and time to first RM intake. The results are consistent with findings from previous studies showing the efficacy of the parenterally administered sodium diclofenac HPβCD formulation (Dietrich et al. 2014; Blair and Plosker 2015; Chiarello et al. 2015) .
No dose-dependent effects were observed in the 4 active groups for any of the evaluated end points. The lack of dose dependency could be related to zero-order kinetics that may be apparent with the localized intramucosal delivery of high concentrations of the drugs. Zero-order kinetics have been observed with several drugs administered subcutaneously, including those from controlled-release systems (Cho et al. 1982; Liu et al. 2007; Mei et al. 2010; Hill et al. 2012) . Interestingly, the 5-mg dose demonstrated slightly better analgesic efficacy over the 6-and 12-h postoperative evaluation period, although this was not significantly different from that observed with the other dose levels. Also, the time until pain onset and RM was longer than in the 12.5-mg and 25-mg groups. The concept of locally/submucosally injected analgesics is a fairly unexplored territory. The local pharmacokinetic profile of submucosal diclofenac HPβCD is not known.
Comparing the pharmacodynamic responses involving pain relief in the present and previous studies (Dietrich et al. 2014 ) with pharmacokinetic data is only possible in relation to the SC administration route of HPβCD diclofenac into the thigh. Thus, previous studies have shown essentially bioequivalence of 75 mg/mL of this formulation when given SC with that when given IM and similar to that with diclofenac sodium as Voltaren given IM (Zeitlinger et al. 2012 ). The drug is rapidly absorbed, with peak concentrations being achieved from SC and IM administration of HPβCD diclofenac at about 1 h, while those from IM diclofenac sodium were evident at 0.45 h, suggesting that the HPβCD may act as a moderate slow-release system. The peak diclofenac concentrations from HPβCD diclofenac are slightly higher following IM compared with both SC-administered drugs (Zeitlinger et al. 2012) . Overall, however, both formulations achieve similar absorption when administered as the sodium salt or the HPβCD formulation. The volumes of distribution, median residence time, and elimination half-life are comparable among the formulations and suggest that the drug is rapidly distributed and eliminated from both formulations. Therefore, an alternative explanation may be that in the context of the dental pain impaction model, a low dose of 5 mg is as efficacious as the higher doses. However, topically applied solutions (e.g., Voltaren) demonstrate a 10× delayed maximal plasma concentration (Altman et al. 2015) , and if submucosal application showed a similarly delayed effect here, the observed findings could be explained in this way. Furthermore, the vasoconstrictor in the LA, administered immediately before the submucosal diclofenac injection, may also have resulted in a delay of systemic distribution of the drug. Hence, the analgesic effects of submucosal diclofenac observed in the present study could be attributable to local or systemic drug effects or a combination of both. We found no evidence for submucosal HPβCD diclofenac injection to have meaningful efficacy as a preemptive analgesic (i.e., having analgesic efficacy beyond 5.5 half-lives), as there were no clinically important differences in terms of analgesic consumption or pain levels over the postoperative week (data not shown).
We evaluated the submucosal HPβCD diclofenac's efficacy in a modified (preemptive) dental pain impaction model for several reasons. First, we were interested in evaluating an approach that would be suitable for use in clinical practice, as LM3 surgery is usually provided as an outpatient procedure and patients would not be able to inject themselves intraorally postoperatively. Second, previous studies have shown that SC injections may cause some pain/discomfort, which would be minimized with a preemptive approach as it allowed submucosal injection following LA.
The main reported ADRs were injection site reactions (i.e., pain or swelling), reported in 14.6% of active group patients, which concurs with previous evaluations (Dietrich et al. 2014; Blair and Plosker 2015) , although this was somewhat surprising given that the injection was given following LA. Previous studies have shown that there were no serious adverse reactions following SC administration of sodium diclofenac HPβCD at 3 dose levels of 25, 50, and 75 mg/mL (Zeitlinger et al. 2012; Dietrich et al. 2014) . Furthermore, Salomone et al. (2014) have shown that few subjects showed local reactions to 50 mg sodium diclofenac HPβCD at the injection sites in the abdomen, gluteus, and quadriceps muscles, with all local reactions being mild to moderate and disappearing by 10 min (i.e., hardening) or 30 min (i.e., swelling and redness).
In the present study, a flap necrosis was observed in 2 subjects, 1 in the 25-mg and 1 in the 50-mg group (Appendix Figs.  2, 3 ). These were highly unusual and not observed previously by the investigators in LM3 surgery. Both resolved without further interventions and without any sequelae. Among the rare adverse skin reactions that have been reported being associated with parenteral injection of diclofenac (Nischal et al. 2009; Kilic et al. 2014; Dadaci et al. 2015) and other drugs (Seremet et al. 2015) , antibiotics (Alkan Bozkaya et al. 2016) , and vaccines (Wronecki and Czernik 1981; Rygnestad and Kvam 1995; Stefano et al. 2017 ) is Nicolau syndrome (livedoid dermatitis or Embolia cutis medicamentosa). This was first reported in 1924 by Freudenthal (Nischal et al. 2009; Kilic et al. 2014; James et al. 2015 ) and is a rare iatrogenic condition characterized by an immediate erythematous skin reaction following injection or ischemic reaction (pallor) sometimes with a reticular pattern leading to necrosis of the skin and underlying tissue, which can be severe and lead to disfigured scarring (James et al. 2015) . We believe that the 2 occurrences of flap necrosis could be unusual mucosal manifestations of Nicolau syndrome. Although previous reports on Nicolau syndrome have implicated diclofenac itself, we cannot rule out HPβCD as a possible cause.
The results of the present study have to be cautiously interpreted due to the limited sample size of this phase II study, which unsurprisingly resulted in some chance imbalances between groups in terms of patient and surgical characteristics. Thus, confounding by these and other unmeasured factors has to be considered.
Overall, this study indicates efficacy, safety, and relative tolerability of diclofenac HPβCD as a local submucosal analgesic. The study provides evidence in support of the novel concept of low-dose local analgesia for the first time. Further studies should include investigation of the study drug's local pharmacokinetics, and larger phase III trials are required to confirm efficacy and safety of low-dose submucosal analgesia for acute pain management.
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